Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arbutus Biopharma CorpABUS · Entity 4953 | Director | June 03, 2021 | June 07, 2021 |
| Damora Therapeutics, Inc.DMRA · Entity 4602 | Director | August 12, 2026 | August 13, 2026 |
| TCGX Acquisition Corp.TCGX · Entity 6504 | Director | August 04, 2026 | August 04, 2026 |
| Vera Therapeutics, Inc.VERA · Entity 4358 | Director | May 21, 2026 | May 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arbutus Biopharma Corp
Report date June 03, 2021 · Filed June 07, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.95 · Expires 2031-06-03 | Direct | 22,000 |
Reported balance
After 2021-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-03 · Grant · Acquired 22,000 · Balance 22,000 F1: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on June 3, 2021, the date of the grant. F2: The options are fully vested and exercisable as of the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on June 3, 2021, the date of the grant.
F2: The options are fully vested and exercisable as of the date of the grant.
Damora Therapeutics, Inc.
Report date August 12, 2026 · Filed August 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.00 · Expires 2036-08-12 | Direct | 30,350 |
Reported balance
After 2026-08-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-12 · Grant · Acquired 30,350 · Balance 30,350 F1: This option represents a right to purchase shares of common stock of the Issuer. This option will vest in equal monthly installments through August 12, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents a right to purchase shares of common stock of the Issuer. This option will vest in equal monthly installments through August 12, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
TCGX Acquisition Corp.
Report date August 04, 2026 · Filed August 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary SharesSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-08-04 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The Class B Ordinary Shares will automatically convert into Class A Ordinary Shares immediately prior to, concurrently with or immediately following the consummation of the Issuer's initial business combination, or at any time prior thereto at the option of the Reporting Person, on a one-for-one basis, subject to adjustment, and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Class B Ordinary Shares will automatically convert into Class A Ordinary Shares immediately prior to, concurrently with or immediately following the consummation of the Issuer's initial business combination, or at any time prior thereto at the option of the Reporting Person, on a one-for-one basis, subject to adjustment, and have no expiration date.
Vera Therapeutics, Inc.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.35 · Expires 2036-05-20 | Direct | 17,084 |
Reported balance
After 2026-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 17,084 · Balance 17,084 F1: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Akero Therapeutics, Inc.
Report date December 09, 2025 · Filed December 09, 2025
Section 16 reporting ended · disclosed 2025-12-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2025-12-09 · Disposition to issuer · Disposed 277,075 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 9, 2025 (such date and time, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of Novo. At the Effective Time, each share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was cancelled and converted into the right to receive (i) cash in an amount equal to $54.00 (the "Closing Consideration") and (ii) one contractual contingent value right (a "CVR") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement) ((i) and (ii), together, the "Merger Consideration"). |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2025-12-09 · Disposition to issuer · Disposed 159,762 · Balance 0 F2: Represents restricted stock units ("Company RSUs") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the Company RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive the Merger Consideration in respect of each such Company RSU. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.23 · Expires 2034-12-16 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-12-09 · Disposition to issuer · Disposed 3,421 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.87 · Expires 2033-12-08 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-12-09 · Disposition to issuer · Disposed 5,032 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.95 · Expires 2032-12-09 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-12-09 · Disposition to issuer · Disposed 2,328 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.10 · Expires 2031-12-08 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-12-09 · Disposition to issuer · Disposed 4,739 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.35 · Expires 2030-12-08 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-12-09 · Disposition to issuer · Disposed 3,527 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.23 · Expires 2034-12-16 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-12-09 · Disposition to issuer · Disposed 292,179 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.87 · Expires 2033-12-08 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-12-09 · Disposition to issuer · Disposed 374,985 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.95 · Expires 2032-12-09 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2025-12-09 · Disposition to issuer · Disposed 233,252 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.10 · Expires 2031-12-08 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2025-12-09 · Disposition to issuer · Disposed 23,809 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.10 · Expires 2031-12-08 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2025-12-09 · Disposition to issuer · Disposed 165,289 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.10 · Expires 2031-12-08 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2025-12-09 · Disposition to issuer · Disposed 87,220 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.35 · Expires 2030-12-08 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2025-12-09 · Disposition to issuer · Disposed 238,973 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.09 · Expires 2029-12-13 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2025-12-09 · Disposition to issuer · Disposed 234,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2029-06-19 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2025-12-09 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 9, 2025 (such date and time, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of Novo. At the Effective Time, each share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was cancelled and converted into the right to receive (i) cash in an amount equal to $54.00 (the "Closing Consideration") and (ii) one contractual contingent value right (a "CVR") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement) ((i) and (ii), together, the "Merger Consideration").
F2: Represents restricted stock units ("Company RSUs") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the Company RSU.
F3: Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive the Merger Consideration in respect of each such Company RSU.
F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2022 Filed Sep 13, 2022 21:13 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | GrantCommon Stock | 1,152 | $8.03 | $9,250.56 |
DisclosureSEC source: 0001104659-22-099797 · tm2225839-1_4seq1.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,148 F1 · shares: These shares were acquired on June 30, 2022 pursuant to the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| May 24, 2022 Filed May 26, 2022 20:14 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 9,925 | $0.00 Strike: $16.14 | $0.00 |
DisclosureSEC source: 0001209191-22-032186 · doc4.xml · derivative · entry 1 Cheng Andrew · CIK 0001778307 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,925 Underlying: Class A Common Stock · 9,925 shares Expires 2032-05-23 F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 20:40 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001104659-22-029521 · tm228282-2_4seq1.xml · derivative · entry 3 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,868 Underlying: Common Stock · 10,000 shares Expires 2028-10-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of this option vested on October 1, 2019, and the remaining 75% of this option shall vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 20:40 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 10,000 | $17.59 | $175,900.00 |
DisclosureSEC source: 0001104659-22-029521 · tm228282-2_4seq1.xml · nonDerivative · entry 2 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,996 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated December 2, 2021, previously adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $17.33 to $17.95, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 20:40 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 10,000 | $0.62 | $6,150.00 |
DisclosureSEC source: 0001104659-22-029521 · tm228282-2_4seq1.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,996 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 19:12 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001104659-22-011501 · tm225280-1_4seq1.xml · derivative · entry 3 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,868 Underlying: Common Stock · 10,000 shares Expires 2028-10-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of this option vested on October 1, 2019, and the remaining 75% of this option shall vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 19:12 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 10,000 | $17.56 | $175,600.00 |
DisclosureSEC source: 0001104659-22-011501 · tm225280-1_4seq1.xml · nonDerivative · entry 2 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,996 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated December 2, 2021, previously adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $17.00 to $17.98, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 19:12 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 10,000 | $0.62 | $6,150.00 |
DisclosureSEC source: 0001104659-22-011501 · tm225280-1_4seq1.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,996 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 10, 2022 Filed Jan 11, 2022 21:40 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001104659-22-003317 · tm222690-1_4seq1.xml · derivative · entry 3 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,868 Underlying: Common Stock · 10,000 shares Expires 2028-10-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of this option vested on October 1, 2019, and the remaining 75% of this option shall vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| January 10, 2022 Filed Jan 11, 2022 21:40 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 10,000 | $0.62 | $6,150.00 |
DisclosureSEC source: 0001104659-22-003317 · tm222690-1_4seq1.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,996 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 21:21 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 53,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001104659-22-001163 · tm221599-1_4seq1.xml · derivative · entry 2 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,712 Underlying: Common Stock · 53,000 shares Expires 2028-09-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of this option vested and became exercisable on September 1, 2019, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 21:21 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 53,000 | $0.62 | $32,595.00 |
DisclosureSEC source: 0001104659-22-001163 · tm221599-1_4seq1.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,996 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 17:15 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | GrantStock Option (Right to Buy) · Derivative | 261,662 | $0.00 Strike: $21.10 | $0.00 |
DisclosureSEC source: 0001104659-21-148685 · tm2135157-2_4seq1.xml · derivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,662 Underlying: Common Stock · 261,662 shares Expires 2031-12-07 F1 · derivative.exercise_date: This option shall vest and become exercisable in 48 equal monthly installments commencing on December 8, 2021. Read SEC document |
| December 02, 2021 Filed Dec 3, 2021 17:20 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 17,500 | $20.18 | $353,150.00 |
DisclosureSEC source: 0001104659-21-146429 · tm2134566-1_4seq1.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,996 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated May 26, 2021, previously adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $19.70 to $20.53, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| November 02, 2021 Filed Nov 3, 2021 16:16 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 17,500 | $22.57 | $394,975.00 |
DisclosureSEC source: 0001104659-21-133653 · tm2131800-2_4seq1.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,496 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated May 26, 2021, previously adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.40 to $23.09, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| October 04, 2021 Filed Oct 5, 2021 16:11 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 17,500 | $21.54 | $376,950.00 |
DisclosureSEC source: 0001104659-21-123091 · tm2129283-2_4seq1.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,996 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated May 26, 2021, previously adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $21.27 to $22.01, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 16:37 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 17,500 | $23.89 | $418,075.00 |
DisclosureSEC source: 0001104659-21-112968 · tm2126986d1_4seq1.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,496 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated May 26, 2021, previously adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $23.53 to $24.395, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 17:38 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 600 | $21.48 | $12,888.00 |
DisclosureSEC source: 0001104659-21-100187 · tm2124177-2_4seq1.xml · nonDerivative · entry 2 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,996 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated May 26, 2021, previously adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $21.37 to $21.93, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 17:38 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 16,900 | $20.81 | $351,689.00 |
DisclosureSEC source: 0001104659-21-100187 · tm2124177-2_4seq1.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,596 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated May 26, 2021, previously adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.43 to $21.22, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| July 02, 2021 Filed Jul 6, 2021 17:52 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 17,500 | $24.78 | $433,650.00 |
DisclosureSEC source: 0001104659-21-089502 · tm2121570-1_4seq1.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,489 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated May 26, 2021, previously adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $24.395 to $25.36, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 20:24 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Options · Derivative | 22,000 | $0.00 Strike: $2.95 | $0.00 |
DisclosureSEC source: 0001447028-21-000040 · wf-form4_162309744639901.xml · derivative · entry 1 Cheng Andrew · CIK 0001778307 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2031-06-03 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on June 3, 2021, the date of the grant. F2 · derivative.exercise_date: The options are fully vested and exercisable as of the date of the grant. Read SEC document |
| May 18, 2021 Filed May 19, 2021 00:12 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | ConversionSeries C Preferred Stock · Derivative | 17,488 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-033807 · doc4.xml · derivative · entry 2 Cheng Andrew · CIK 0001778307 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Class A Common Stock · 17,488 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series C Preferred Stock automatically converted into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and had no expiration date. F1 · derivative.exercise_date: The Series C Preferred Stock automatically converted into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and had no expiration date. F1 · derivative.expiration_date: The Series C Preferred Stock automatically converted into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and had no expiration date. F2 · ownership.nature: The shares are held of record by Andrew K. Cheng, as Trustee of the Andrew Cheng 2010 Trust UA 10-26-2010. Read SEC document |
| May 18, 2021 Filed May 19, 2021 00:12 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | ConversionClass A Common Stock | 17,488 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-033807 · doc4.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 17,488 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series C Preferred Stock automatically converted into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and had no expiration date. F2 · ownership.nature: The shares are held of record by Andrew K. Cheng, as Trustee of the Andrew Cheng 2010 Trust UA 10-26-2010. Read SEC document |
| May 13, 2021 Filed May 18, 2021 00:35 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 9,925 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0001209191-21-033337 · doc4.xml · derivative · entry 1 Cheng Andrew · CIK 0001778307 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,925 Underlying: Class A Common Stock · 9,925 shares Expires 2031-05-12 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of May 13, 2022 or the 2022 annual meeting of stockholders. Read SEC document |
| January 10, 2021 Filed Jan 11, 2022 21:40 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 10,000 | $19.55 | $195,500.00 |
DisclosureSEC source: 0001104659-22-003317 · tm222690-1_4seq1.xml · nonDerivative · entry 2 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,996 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated December 2, 2021, previously adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $19.225 to $19.91, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| January 07, 2021 Filed Jan 11, 2021 19:57 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001104659-21-003113 · tm212775-1_4seq1.xml · derivative · entry 3 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,712 Underlying: Common Stock · 20,000 shares Expires 2028-09-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of this option vested and became exercisable on September 1, 2019, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| January 07, 2021 Filed Jan 11, 2021 19:57 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 20,000 | $0.62 | $12,300.00 |
DisclosureSEC source: 0001104659-21-003113 · tm212775-1_4seq1.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 362,989 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 31, 2020 Filed Jan 11, 2021 19:57 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | GiftCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-003113 · tm212775-1_4seq1.xml · nonDerivative · entry 2 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 359,989 F1 · shares: The shares reported in this transaction represent a bona fide charitable gift to a donor advised fund. The Reporting Person does not have any pecuniary interest in the fund's assets. Read SEC document |
| December 28, 2020 Filed Dec 29, 2020 16:53 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 7,480 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001104659-20-140178 · tm2039529-1_4seq1.xml · derivative · entry 2 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,712 Underlying: Common Stock · 7,480 shares Expires 2028-09-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of this option vested and became exercisable on September 1, 2019, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| December 28, 2020 Filed Dec 29, 2020 16:53 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 7,480 | $0.62 | $4,637.60 |
DisclosureSEC source: 0001104659-20-140178 · tm2039529-1_4seq1.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,989 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 16:19 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,500 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001104659-20-139119 · tm2039296d1_4.xml · derivative · entry 4 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,192 Underlying: Common Stock · 10,500 shares Expires 2028-09-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of this option vested and became exercisable on September 1, 2019, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 16:19 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 10,500 | $0.62 | $6,510.00 |
DisclosureSEC source: 0001104659-20-139119 · tm2039296d1_4.xml · nonDerivative · entry 3 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,509 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2020 Filed Dec 23, 2020 16:19 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | GiftCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-139119 · tm2039296d1_4.xml · nonDerivative · entry 2 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,009 F2 · shares: The shares reported in this transaction represent a bona fide charitable gift to a donor advised fund. The Reporting Person does not have any pecuniary interest in the fund's assets. Read SEC document |
| December 11, 2020 Filed Dec 23, 2020 16:19 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | GiftCommon Stock | 50 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-139119 · tm2039296d1_4.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,509 F1 · shares: The shares reported in this transaction represent a bona fide gift. Read SEC document |
| December 08, 2020 Filed Dec 9, 2020 20:47 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | GrantStock Option (Right to Buy) · Derivative | 242,500 | $0.00 Strike: $28.35 | $0.00 |
DisclosureSEC source: 0001104659-20-133846 · tm2038113-1_4seq1.xml · derivative · entry 2 Cheng Andrew · CIK 0001778307 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,500 Underlying: Common Stock · 242,500 shares Expires 2030-12-07 F2 · derivative.exercise_date: This option shall vest and become exercisable in 48 equal monthly installments, commencing on December 8,2020. Read SEC document |
| June 30, 2020 Filed Dec 9, 2020 20:47 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | GrantCommon Stock | 1,245 | $17.07 | $21,249.66 |
DisclosureSEC source: 0001104659-20-133846 · tm2038113-1_4seq1.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,559 F1 · shares: These shares were acquired on June 30, 2020 pursuant to the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 20:58 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Options · Derivative | 22,000 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0001447028-20-000065 · wf-form4_159104509367362.xml · derivative · entry 1 Cheng Andrew · CIK 0001778307 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2030-05-28 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on May 28, 2020, the date of the grant. F2 · derivative.exercise_date: The options are fully vested and exercisable as of the date of the grant. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 18:16 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | GrantCommon Stock | 1,025 | $18.87 | $19,337.65 |
DisclosureSEC source: 0001104659-20-001031 · a4.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,314 F1 · shares: These shares were acquired on December 31, 2019 pursuant to the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 13, 2019 Filed Dec 13, 2019 21:08 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | GrantStock Option (Right to Buy) · Derivative | 234,000 | $0.00 Strike: $21.09 | $0.00 |
DisclosureSEC source: 0001104659-19-072698 · a4.xml · derivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,000 Underlying: Common Stock · 234,000 shares Expires 2029-12-12 F1 · derivative.exercise_date: This option shall vest and become exercisable in 48 equal monthly installments, commencing on December 13, 2019. Read SEC document |
| August 17, 2019 Filed Aug 20, 2019 20:18 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Options · Derivative | 60,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001447028-19-000057 · wf-form4_156633226904329.xml · derivative · entry 1 Cheng Andrew · CIK 0001778307 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2029-08-17 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on August 16, 2019, the trading day immediately preceding the date of the grant. F2 · derivative.exercise_date: The option will vest and become exercisable in three equal annual installments beginning one year from the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.